摘要
由于肿瘤病理复杂性,临床治疗中对于多种药物联合使用的需求日益迫切。多药联用可同时作用于多通路和多靶点发挥协同增效作用,然而目前临床多药联用的递送策略仍有较大优化空间。纳米药物递送系统可精准调控药物多组分灵活荷载,并携载药物克服生理、病理屏障,实现肿瘤组织、细胞的有效富集,完成持续、可控和靶向递送,实现抗肿瘤增效减毒,已在肿瘤多药联合治疗领域展现出广阔的前景,并成为药物研发的新方向之一。本文对近年来肿瘤联合用药治疗策略及其递送系统的研究进展进行了综述,并分析和探讨了多药联用型纳米递送系统的应用瓶颈、现有研究面临的挑战及未来的发展趋势。
Due to the complexity of tumor pathology,the demand for the combined use of multiple drugs in clinical treatment has become increasingly clear-cut.Multi-drug combination can act on multiple pathways and multiple targets simultaneously to exert synergistic effects.However,the current delivery strategy for multi-drug combination still needs to be optimized.Nano-drug delivery systems can carry drugs to overcome physiological and pathological barrier to target tumor tissues and cells,achieve the goal of continuous,controllable,and targeted delivery,and enhance the efficacy of anti-tumor synergism and detoxification.To meet the new requirements for smarter and more accurate antitumor multi-drug combinational therapy,the nano-drug delivery system has been well-designed to realize more functions.For instance,delivery of multiple drugs in accurate proportions and doses can make the multi-drug synergistic effect more precise;stimulus-responsive drug release can improve selectivity and reduce side effects;controlling the time-course relationship of multiple drugs can realize sequential drug combination effect.It has shown broad prospects in the field of tumor multidrug therapy and has become one of the new directions of research and development.This article reviews the recent developments in the application of tumor drug combination therapy strategies and their delivery systems,and analyzes the new requirements and challenges of multidrug combination for the development of nano-drug delivery systems.
作者
江文心
张华清
丁杨
周建平
JIANG Wen-xin;ZHANG Hua-qing;DING Yang;ZHOU Jian-ping(State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China;Key Laboratory of Drug Quality Control and Pharmacovigilance,Ministry of Education,China Pharmaceutical University,Nanjing 210009,China;NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients,Nanjing 210009,China)
出处
《药学学报》
CAS
CSCD
北大核心
2022年第1期1-12,I0003,共13页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81872819,82073401,82073795)
中国药科大学“双一流”建设计划(CPU2018GY26)
江苏省高等学校重点学科发展基金资助项目.
关键词
抗肿瘤
药物联用
纳米医学
药物递送系统
多模式治疗
antitumor
drug combination
nanomedicine
drug delivery system
multimodal treatment
